Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications.
about
What is the functional role of the thalidomide binding protein cereblon?Multiple myeloma cancer stem cellsCancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistanceTargeting the biophysical properties of the myeloma initiating cell niches: a pharmaceutical synergism analysis using multi-scale agent-based modelingTranscriptional repression of Bim by a novel YY1-RelA complex is essential for the survival and growth of Multiple MyelomaCombination with a defucosylated anti-HM1.24 monoclonal antibody plus lenalidomide induces marked ADCC against myeloma cells and their progenitorsDosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients.Lenalidomide for the treatment of relapsed and refractory multiple myeloma.Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2.Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition.Minor clone provides a reservoir for relapse in multiple myelomaEstablishment and characterization of bortezomib-resistant U266 cell line: constitutive activation of NF-κB-mediated cell signals and/or alterations of ubiquitylation-related genes reduce bortezomib-induced apoptosisUpdate on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.Identification of pluripotent and adult stem cell genes unrelated to cell cycle and associated with poor prognosis in multiple myeloma.Bortezomib reduces the tumorigenicity of multiple myeloma via downregulation of upregulated targets in clonogenic side population cells.Phenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell linesPhase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoproteinHigh throughput quantitative reverse transcription PCR assays revealing over-expression of cancer testis antigen genes in multiple myeloma stem cell-like side population cells.Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myelomaDifferential remodeling of extracellular matrices by breast cancer initiating cells.The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias.MicroRNA-451 regulates stemness of side population cells via PI3K/Akt/mTOR signaling pathway in multiple myeloma.Progress in myeloma stem cellsA rare fraction of drug-resistant follicular lymphoma cancer stem cells interacts with follicular dendritic cells to maintain tumourigenic potentialNatural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model.Mitochondrial-Targeted Decyl-Triphenylphosphonium Enhances 2-Deoxy-D-Glucose Mediated Oxidative Stress and Clonogenic Killing of Multiple Myeloma CellsIn multiple myeloma, bone-marrow lymphocytes harboring the same chromosomal abnormalities as autologous plasma cells predict poor survivalPharmacologic screens reveal metformin that suppresses GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomib.Isocorydine targets the drug-resistant cellular side population through PDCD4-related apoptosis in hepatocellular carcinomaStemness of B-cell progenitors in multiple myeloma bone marrow.Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma.Senescence-associated secretory phenotype favors the emergence of cancer stem-like cells.Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1Paclitaxel-Fe3O4 nanoparticles inhibit growth of CD138(-) CD34(-) tumor stem-like cells in multiple myeloma-bearing mice.Biological characteristics of side population cells in a self-established human ovarian cancer cell lineRARα2 expression confers myeloma stem cell featuresBruceantin inhibits multiple myeloma cancer stem cell proliferation.Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levelsWhy proteasome inhibitors cannot ERADicate multiple myeloma.
P2860
Q24635072-3ABD5294-4100-4D4C-A298-0C37969D377DQ26752365-2F798D31-03C3-4BCB-91AB-AD5532E4DCFEQ26785497-73335E81-4BB1-49D4-A1CE-CA153BF1DEC9Q26865927-7A391BA5-EE31-4C64-AD50-4B195B69E697Q27334339-CE52A665-9E80-427E-A740-124054DBED0DQ28534603-8BA2F383-1F20-4F0D-93A7-A47D866D9823Q28537997-205BDDA3-0489-4BD3-BC54-0DCDFD32E2FFQ33400076-17DA08CC-E5D4-4144-97B9-08A40AC79EF1Q33403183-586651A1-E0AB-49B5-844C-C0C1A938CDA6Q34017354-2716A146-1748-456A-8DCF-226320ED1BDCQ34075096-9FDD78FB-B91B-4B21-B5FB-A409E21EC906Q34147170-D4CB2517-DC88-4A59-9FE1-19B9A5B12AF6Q34179925-BDACC939-D375-48E3-8A72-88EF975F0BE9Q34253548-A506321F-0DD8-4D54-849B-8F2CA0055F02Q34364560-2246FF25-D23C-4765-A477-3AD568CBEECFQ34612981-23B65010-0BC8-4F04-884B-C3D88C3FC7EFQ35128148-AD77FC2E-E40E-4ABE-9445-6F0217F83591Q35187824-B53AB9DB-C43B-4620-8280-7873D1C20058Q35194860-5F56A300-9CD5-4043-A178-5FDD66284C0EQ35260732-F3C2EA5D-56EE-4B5C-8B9A-C7F8193CA58FQ35544277-649D7FC7-EC0D-40E8-B77B-E96F1AD1ECBBQ35552693-FBA5C8C6-9473-445A-952C-B5C23F70CE8DQ35615252-32F7DA0C-53B1-4BE2-BD40-010CD193F3CAQ35824980-093E6E48-475D-4A75-80FA-FBAFC37004E0Q36028412-368138DC-E4EE-42D2-B2F2-54535C1C1CB8Q36094697-2D415C1E-84AF-4FDE-8B17-6D042E9779F7Q36208283-78E55154-853F-4BD0-9424-8479A9DA854AQ36208638-5C9864CE-B60A-421F-853B-0F1FDAF53A66Q36254571-86F26238-ADD6-4C74-A663-EFD700E52195Q36327378-6E2CB8FC-4574-4A79-880D-8A7FF68842DCQ36405908-F76C104C-6F2B-4820-B2EB-2427B2D0F61AQ36474588-1E152BF7-6B92-4BB0-B081-29BCE6759813Q36525196-6254CC06-C041-42EB-8C57-7E54867877DBQ36717999-AF647679-F880-4AFA-9FB3-A07C29FED0E8Q36776906-DF660A08-C6EA-41AB-89BC-C07940370676Q37001978-EF3EA475-3747-491A-99BC-D4F008C4453CQ37113087-DCCF3A6D-157F-47CA-8011-7D14B3DCCABFQ37283018-97CA9AFD-6B1A-4FED-8F95-A1569686F5FEQ37325843-6BE9D73E-619A-463F-8682-8EEA6A3CB9FEQ37393383-59937DA1-DC05-43EA-AFD6-DA04BB419713
P2860
Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Lenalidomide targets clonogeni ...... gic and clinical implications.
@ast
Lenalidomide targets clonogeni ...... gic and clinical implications.
@en
type
label
Lenalidomide targets clonogeni ...... gic and clinical implications.
@ast
Lenalidomide targets clonogeni ...... gic and clinical implications.
@en
prefLabel
Lenalidomide targets clonogeni ...... gic and clinical implications.
@ast
Lenalidomide targets clonogeni ...... gic and clinical implications.
@en
P2093
P2860
P1433
P1476
Lenalidomide targets clonogeni ...... gic and clinical implications.
@en
P2093
Constantine S Mitsiades
Dana Cholujova
David Cervi
Jacob Laubach
Jake Delmore
Jan Sedlak
Jana Jakubikova
John F Daley
Maria Kost-Alimova
Melissa Ooi
P2860
P304
P356
10.1182/BLOOD-2010-02-267344
P407
P577
2011-02-14T00:00:00Z